Stock Analiz

Neogenomics Inc. (NEO) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Neogenomics’s revenue went from $232M in fiscal 2016 to $727M in fiscal 2025, growth of about 13.5% a year.

Net income in fiscal 2025 was -$108M, a net margin of -14.9%; the best year in this period was 2019 with $8M.

Over the twelve months to September 30, 2026, revenue was $788M and net income -$32M.

Free cash flow was -$22M in fiscal 2025 and positive in 4 of the 10 years shown.

The diluted share count rose 65% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $232M162017: $240M172018: $277M182019: $409M192020: $444M202021: $484M212022: $510M222023: $592M232024: $661M242025: $727M25$727M
Net income
2016: -$6M162017: -$396000172018: $3M182019: $8M192020: $4M202021: -$8M212022: -$144M222023: -$88M232024: -$79M242025: -$108M25-$108M
Free cash flow
2016: $14M162017: $4M172018: $30M182019: $3M192020: -$28M202021: -$91M212022: -$97M222023: -$31M232024: -$34M242025: -$22M25-$22M
EPS (diluted)
2016: $-0.40162017: $-0.14172018: $0.07182019: $0.08192020: $0.04202021: $-0.07212022: $-1.16222023: $-0.70232024: $-0.62242025: $-0.8425$-0.84

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$788M$727M$661M$592M$510M$484M$444M$409M$277M$240M$232M
Gross profit$353M$314M$290M$245M$188M$187M$186M$197M$127M$102M$98M
Operating income-$49M-$116M-$92M-$108M-$158M-$119M-$14M$13M$10M$3M$2M
Net income-$32M-$108M-$79M-$88M-$144M-$8M$4M$8M$3M-$396000-$6M
EPS (diluted)$-0.24$-0.84$-0.62$-0.70$-1.16$-0.07$0.04$0.08$0.07$-0.14$-0.40
R&D$39M$37M$31M$27M$30M$22M$8M$8M$3M$4M$5M
Revenue growth—+10.1%+11.7%+16.1%+5.2%+9.0%+8.7%+47.7%+15.2%+3.6%+4536.2%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$4M$5M$7M-$2M-$66M-$27M$1M$23M$45M$18M$21M
Capital spending-$33M-$27M-$41M-$29M-$31M-$64M-$29M-$20M-$14M-$14M-$8M
Free cash flow-$29M-$22M-$34M-$31M-$97M-$91M-$28M$3M$30M$4M$14M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$35M$41M$33M$25M$25M$22M$10M$10M$7M$6M$5M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$160M$367M$342M$263M$515M$296M$173M$10M$13M$13M
Debt—$409M$605M$612M$611M$613M$216M$127M$124M$108M$109M
Equity—$837M$902M$942M$998M$1.1B$694M$507M$320M$172M$162M
Total assets—$1.4B$1.6B$1.7B$1.7B$1.9B$988M$710M$505M$344M$337M
Shares (diluted)129M128M127M126M124M120M112M104M92M79M78M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin44.8%43.2%43.9%41.3%36.9%38.6%41.8%48.1%46.0%42.4%42.3%
Operating margin-6.3%-15.9%-13.9%-18.2%-30.9%-24.5%-3.1%3.2%3.6%1.2%0.9%
Net margin-4.1%-14.8%-11.9%-14.9%-28.3%-1.7%0.9%2.0%0.9%-0.2%-2.6%
FCF margin-3.6%-3.0%-5.1%-5.2%-19.0%-18.8%-6.2%0.8%11.0%1.8%6.0%
ROIC—-9.1%-6.0%-6.3%-8.9%-3.8%-1.2%1.6%1.6%0.8%0.6%
ROE—-12.9%-8.7%-9.3%-14.4%-0.8%0.6%1.6%0.8%-0.2%-3.8%

Frequently asked questions

What is Neogenomics’s annual revenue?

$727M in fiscal 2025 and $788M over the twelve months to September 30, 2026.

How much profit does Neogenomics make?

Net income was -$108M in fiscal 2025 (net margin -14.9%).

Is Neogenomics’s revenue growing?

Yes: revenue rose 10.1% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.